Journal Mobile Options
Table of Contents
Vol. 17, No. 1, 2000
Issue release date: 2000
Dig Surg 2000;17:36–41
(DOI:10.1159/000018798)

Adenocarcinoma of the Distal Bile Duct

A Clinicopathologic Outcome Analysis after Curative Resection

Bortolasi L. · Burgart L.J. · Tsiotos G.G. · Luque-de León E. · Sarr M.G.
Departments of aSurgery and bLaboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Primary distal bile duct adenocarcinomas (DBDAs) are unusual neoplasms, necessitating pancreaticoduodenectomy for cure. The aims of this study were to evaluate the prognostic importance of lymphatic and perineural invasion, long-term outcome of patients after resection, and differences in outcome with hilar cholangiocarcinoma and pancreatic carcinoma. Methods: The medical records and histopathological slides of 15 patients (8 men and 7 women) with documented DBDA after curative pancreaticoduodenectomy were reviewed. Results: Nine standard and 6 pylorus-preserving pancreaticoduodenectomies were performed. TNM staging included 1, 3, 2, 8, and 1 patient in stages I, II, III, and IVA and IVB, respectively. Lymphatic and perineural invasion was present in 4 (27%) and 9 (60%) patients, respectively. With multivariate analysis only serum bilirubin was a significant prognostic factor. Median survival was 21 months, and 2- and 5-year actuarial survivals were 40 and 20%, respectively. Median survival with adjuvant therapy (n = 6) was 21 months, with 5-year survival of 33%. Five-year actuarial survivals when lymphatic or perineural invasion was present were 0 and 11%, respectively. Conclusion: DBDA is aggressive, but entails a better prognosis than pancreatic ductal or more proximal bile duct carcinoma. Lymphatic and/or perineural invasion worsen survival.

Copyright © 2000 S. Karger AG, Basel



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma: A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–475.
  2. Tompkins RK, Thomas D, Wile A, Longmire WP: Prognostic factors in bile duct carcinoma. Analysis of 96 cases. Ann Surg 1981;194:447–457.

    External Resources

  3. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM: Outcome after curative resections of cholangiocarcinoma. Arch Surg 1993;128:871–879.
  4. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tsukioka Y, Miyazaki I: Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion. Surgery 1995;117:616–623.
  5. Allema JH, Reinders ME, van Gilik TM, Koelemay MJ, van Leeuwen DJ, de Wit LT, Gouma DJ, Obertop H: Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995;75:2069–2076.
  6. Bhuiya MR, Nimura Y, Kamiya J, Kondo S, Fakata S, Hayakawa N, Shinoya S: Clinicopathologic studies in perineural invasion of bile duct carcinoma. Ann Surg 1992;215:344–349.
  7. Bhuiya MR, Nimura Y, Kamiya J, Kondo S, Nagino M, Hayakawa N: Clinicopathologic factors influencing survival of patients with bile duct carcinoma: Multivariate statistical analysis. World J Surg 1993;17:653–657.
  8. Kayahara M, Nagakawa T, Tsukioka Y, Ohta T, Ueno K, Miyazaki I: Neural invasion and nodal involvement in distal bile duct cancer. Hepatogastroenterology 1994;41:190–194.
  9. Kayahara M, Nagakawa T, Ueno K, Ohta T, Tkeda T, Miyazaki I: Lymphatic flow in carcinoma of the distal bile duct on a clinicopathologic study. Cancer 1993;72:2112–2117.
  10. Nitecki SS, Sarr MG, Colby TV, van Heerden JA: Long-term survival after resection for ductal adenocarcinoma of the pancreas: Is it really improving? Ann Surg 1995;221:59–66.
  11. Joesting DR, Beart RW Jr, van Heerden JA, Weiland LH: Improving survival in adenocarcinoma of the duodenum. Am J Surg 1981;141:228–231.

    External Resources

  12. Monson JR, Donohue JH, McEntee GP, McIlrath DC, van Heerden JA, Shorter RG, Nagorney DM, Ilstrup DM: Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991;126:353–357.
  13. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF: Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712–1715.
  14. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman JA, Zahurac ML, Grochow LB, Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Ann Surg 1997;226:248–260.
  15. Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM: Surgical management of intrahepatic cholangiocarcinoma: A 31-year experience. J Hepatobiliary Pancreat Surg 1998;5:41–47.
  16. Kopelson G, Galdabini J, Warshaw AL, Gunderson LL: Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: Implications for adjuvant therapy. Int J Radiat Biol Phys 1981;7:413–417.
  17. Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW: Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267–274.
  18. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.
  19. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;87:2006–2010.
  20. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurac ML, Dooley WC, Coleman JA, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL: Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. Ann Surg 1997;225:621–636.
  21. Alden ME, Waterman FM, Topham AK, Barbot DJ, Shapiro MJ, Mohiuddin M: Cholangiocarcinoma: Clinical significance of tumor location along the extrahepatic bile duct. Radiology 1995;197:511–516.
  22. Buchler M, Friess H, Klempa I, Hermaneck P, Sulkowski U, Becker H, Schafmayer A, Baca I, Lorenz D, Meister R, Kremer B, Wagner P, Witte J, Zurmayer EL, Saeger H-D, Rieck B, Dollinger P, Glaser P, Teichmann R, Konradt J, Gous W, Dennier H-J, Welzel D, Beger HF: Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 1992;163:125–131.
  23. Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, Fegiz G, Fissi S, Roviaro G, Peracchia A: Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: A prospective, controlled, randomized clinical trial. Surgery 1995;117:26–31.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50